TβRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity

Carcinogenesis

Volumn 29, Issue 3, 2008, Pages 528-535

  Finger, Elizabeth C ^a   Turley, Ryan S ^a   Dong, Mei ^a   How, Tam ^a   Fields, Timothy A ^a   Blobe, Gerard C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; MATRIGEL; MESSENGER RNA; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR TYPE 3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; PRIMER DNA;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE LOCUS; GENE LOSS; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; ANIMAL; CANCER INVASION; CELL PROLIFERATION; GENETICS; LUNG TUMOR; MOUSE; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; DNA, COMPLEMENTARY; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 40949157944     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm289     Document Type: Article

References (44)

1. Shi,Y. et al. (2003) Mechanism of TGF-beta signaling from cell membrane to the nucleus. Cell, 113, 685-700.
2. Wang,X.F. et al. (1991) Expression cloning and characterization of the TGF-beta type III receptor. Cell, 67, 797-805.
3. Elliott,R.L. et al. (2005) Role of transforming growth factor beta in human cancer. J. Clin. Oncol., 23, 2078-2093.
4. Bierie,B. et al. (2006) TGF-beta and cancer. Cytokine Growth Factor Rev., 17, 29-40.
5. Roberts,A.B. et al. (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl Acad. Sci. USA, 100 8621-8623.
6. Derynck,R. et al. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 425, 577-584.
7. Lopez-Casillas,F. et al. (1991) Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell, 67, 785-795.
8. Eickelberg,O. et al. (2002) Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J. Biol. Chem., 277, 823-829.
9. Lopez-Casillas,F. et al. (1993) Betaglycan presents ligand to the TGF beta signaling receptor. Cell, 73, 1435-1444.
10. Stenvers,K.L. et al. (2003) Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol. Cell Biol., 23, 4371-4385.
11. Blobe,G.C. et al. (2001) Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. J. Biol. Chem. 276, 24627-24637.
12. Brown,C.B. et al. (1999) Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science, 283 2080-2082.
13. Deng,X. et al. (1999) Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta, receptor type III. Cell Growth Differ., 10, 11-18.
14. Blobe,G.C. et al. (2001) A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J. Biol. Chem., 276, 39608-39617.
15. Park,C. et al. (2002) Effects of transforming growth factor beta (TGF-beta) receptor on lung carcinogenesis. Lung Cancer, 38, 143-147.
16. Anumanthan,G. et al. (2005) Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. Br. J. Cancer, 93, 1157-1167.
17. Nagatake,M. et al. (1996) Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res., 56, 2718-2720.
18. Uchida,K. et al. (1996) Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res., 56, 5583-5585.
19. de Jonge,R.R. et al. (1997) Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol. Res., 9, 89-98.
20. Turley,R.S. et al. (2007) The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res, 67, 1090-1098.
21. Beer,D.G. et al. (2002) Gene-expression proffies predict survival of patients, with lung adenocarcinoma. Nat. Med., 8, 816-824.
22. Bhattacharjee,A. et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA, 98, 13790-13795.
23. Powell,C.A. et al. (2003) Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am. J. Respir Cell Mol. Biol., 29 157-162.
24. Garber,M.E. et al. (2001) Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA, 98, 13784-13789.
25. Raponi,M. et al. (2006) Gene expression signatures for predicting prognosis of squamous; cell and adenocarcinomas of the lung. Cancer Res., 66, 7466-7472.
26. Ragnarsson,G, et al. (1999) Loss of heterozygosity at chromosome 1p in different solid human tumours: Association with survival. Br J. Cancer, 79, 1468-1474.
27. Dong,M. et al. (2007) The type III TGF-beta receptor suppresses breast cancer progression. J. Clin. Invest., 117, 206-217.
28. Robinson,S.P. et al. (1992) Transforming growth factor beta 1: lack of in vivo antitumor activity on A549 and Wehi 3BD+ tumors. Anticancer Res., 12, 73-79.
29. Kim,W.S. et al. (1999) Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma: Of the lung. Anticancer Res., 19, 301-306.
30. Valster,A. et al. (2005) Cell migration and invasion assays. Methods, 37, 208-215.
31. Repesh,L.A. (1989) A new in 'vitro assay for quantitating tumor cell invasion. Invasion Metastasis, 9, 192-208.
32. Bandyopadhyay,A. et al. (2002) Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene, 21, 3541-3551.
33. Chen,M.F. et al. (2006) Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int. J. Radiat. Oncol. Biol. Phys., 64, 581-591.
34. Jemal,A. et al. (2006) Cancer statistics, 2006. CA Cancer J. Clin., 56, 106-130.
35. Herman,J.G. et al. (2003,), Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 349, 2042-2054.
36. Hempel,N. et al. (2007) Loss of betaglycan expression in ovarian cancer. role in motility and impion. Cancer Res., 67, 5231-5238.
37. Kirkbride,K.C. et al. (2005) Cell-surface co-receptors: Emerging roles in signaling and human disease. Trends Biochen Sci., 30 611-621.
38. Kirikoshi,H. et al. (2002) Expression of human GIPC1 in normal tissues, cancer cell lines, and primary tumors. Int. J. Mol. Med., 9, 509-513.
39. Chen,W. et al. (2003) Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 301, 1394-1397.
40. Lefkowitz,R.J. et al. (2005) Transduction of receptor signals by beta-arrestins. Science, 308, 512-517.
41. Lopez-Casillas,F. et al. (1994) Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J. Cell Biol., 124, 557-568.
42. Bandyopadhyay,A. et al. (1999) A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res., 59, 5041-5046.
43. Bandyopadbyay,A. et al. (2005) Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate, 63, 81-90.
44. Lopez-Gonzalez,J.S. et al. (2002) Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines. Lung Cancer, 38, 149-158.